Narcolepsy Market Trends, Innovation, and Future Growth Outlook to 2034 – DelveInsight | Taisho Pharmaceutical, Jazz Pharma, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical

Posted on
by

Narcolepsy Market Trends, Innovation, and Future Growth Outlook to 2034 – DelveInsight | Taisho Pharmaceutical, Jazz Pharma, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical

 

DelveInsight’s “Narcolepsy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Narcolepsy, historical and forecasted epidemiology as well as the Narcolepsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Get a Free sample for the Narcolepsy Market Report:

https://www.delveinsight.com/report-store/narcolepsy-market

 

Some of the key facts of the Narcolepsy Market Report:

  • According to a 2024 analysis, the narcolepsy market across the 7MM was valued at nearly USD 2.5 billion, driven by rising disease awareness, better diagnostic rates, and the growing availability of treatment options.

  • In February 2026, Harmony Biosciences announced that the U.S. Food and Drug Administration has approved a supplemental new drug application for Wakix (pitolisant) tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.

  • In January 2026, Alkermes plc announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to alixorexton for the treatment of narcolepsy type 1.

  • In July 2025, Takeda’s oral narcolepsy therapy, oveporexton, successfully achieved both primary and secondary endpoints in two Phase III clinical studies. The FirstLight (NCT06470828) and RadiantLight (NCT06505031) trials demonstrated positive results across all endpoints in patients with narcolepsy type 1 (NT1) following 12 weeks of treatment.

  • In June 2025, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has unveiled new Phase 4 findings highlighting the effectiveness of Xywav® (a low-sodium oxybate formulation containing calcium, magnesium, potassium, and sodium) in treating individuals with narcolepsy. The results are part of four late-breaking abstracts from Jazz presented as oral sessions at SLEEP 2025, all of which were chosen by the Associated Professional Sleep Societies (APSS) for their scientific significance and innovation. Xywav remains the only FDA-approved low-sodium oxybate therapy for managing cataplexy or excessive daytime sleepiness (EDS) in narcolepsy patients aged 7 and older, as well as for adults with idiopathic hypersomnia. The recommended dosage ranges from 6 to 9 grams per night.

  • In May 2025, Takeda (TSE: 4502/NYSE: TAK) announced that the New England Journal of Medicine has published results from a Phase 2b trial evaluating oveporexton (TAK-861) in individuals with narcolepsy type 1 (NT1). Oveporexton is an investigational oral therapy that selectively targets orexin receptor 2 (OX2R) to restore orexin signaling, which is deficient in NT1. The trial results showed significant improvements in both objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy episodes, and meaningful improvements in overall disease severity and quality of life across all tested doses when compared to placebo after eight weeks of treatment.

  • In May 2025, A recent Phase IIb clinical trial highlighted encouraging results for Takeda’s oral orexin receptor 2 (OX2R)-selective agonist in treating narcolepsy type 1 (NT1). Published in the New England Journal of Medicine, the data indicates that oveporexton (TAK-861) notably reduced disease severity and helped participants achieve wakefulness levels close to normal. Takeda reports that the therapy is intended to target the core issue in NT1—orexin deficiency—in this long-term neurological disorder.

  • According to Narcolepsy Network Organization, narcolepsy is an under diagnosed sleep disorder which is most common among the adults as compared to the pediatrics.

  • Narcolepsy is classified into two types: Type 1 (with cataplexy) and Type 2 (without cataplexy). Orphanet estimates that NT1 affects between 1 in 2,000 and 1 in 5,000 individuals, making it the more commonly recognized form.

  • As per our secondary analysis based on a large representative sample of the US general population, current prevalence of narcolepsy is reported at 37.7/100,000 individuals (12.6/100,000 for NT1, 25.1/100,000 for NT2), and a yearly occurrence of 2.6/100,000.

  • Prevalence of narcolepsy in Europe was nearly 47 patients per 100,000 persons, with a yearly occurrence of 0.64–1.37 per 100,000.

  • As per our secondary analysis, the worldwide prevalence of narcolepsy is approximately 1 in 2,000, while in Japan, it is approximately 37.5 per 100,000 persons. the average age of onset in Japan is 18 years.

  • According to our secondary analysis, the prevalence for NT1 is 14 per 100,000 people and 65.4 per 100,000 people for NT2. The prevalence is highest in the late teens to early twenties with a 50% greater female predominance in the US.

  • Key Narcolepsy Companies: NLS Pharmaceutics, Suven Life SciencesAlkermes, Inc., Jazz Pharmaceuticals, Taisho Pharmaceutical, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical, Theranexus, NLS Pharmaceutics, Axsome Therapeutics, Inc, Takeda, Pfizer, Avadel, Balance Therapeutics, and others

  • Key Narcolepsy Therapies: QUILIENCE (mazindol ER), Samelisant (SUVN-G3031), NLS-2, ALKS 2680, JZP258 (XYWAV), TS-091 5mg, JZP-258, SUVN-G3031, JNJ-17216498, Modafinil, sodium oxybate, THN102 300/3, Mazindol, AXS-12 (Reboxetine), TAK-861, PF-03654746, FT218, BTD-001, and others

  • The Narcolepsy epidemiology based on gender analyzed that females are more affected with narcolepsy (type1) than males

  • The Narcolepsy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Narcolepsy pipeline products will significantly revolutionize the Narcolepsy market dynamics.

 

Narcolepsy Overview

Narcolepsy is a chronic neurological disorder characterized by the brain’s inability to regulate sleep-wake cycles normally. People with narcolepsy experience excessive daytime sleepiness and uncontrollable episodes of falling asleep during the day, regardless of the amount of nighttime sleep. These sudden sleep attacks can occur during any type of activity.

 

To Know in detail about the Narcolepsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Narcolepsy Market Forecast

 

Narcolepsy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Narcolepsy Epidemiology Segmentation:

The Narcolepsy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Diagnosed Prevalent Cases of Narcolepsy in the 7MM

  • Subtype-specific Diagnosed Prevalent Cases of Narcolepsy in the 7MM

  • Age-specific Diagnosed Prevalent Cases of Narcolepsy in the 7MM

  • Treated Cases of Narcolepsy in the 7MM

 

Download the report to understand which factors are driving Narcolepsy epidemiology trends @ Narcolepsy Epidemiology Forecast

 

Narcolepsy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Narcolepsy market or expected to get launched during the study period. The analysis covers Narcolepsy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Narcolepsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Narcolepsy Therapies and Key Companies

  • QUILIENCE (mazindol ER): NLS Pharmaceutics

  • Samelisant (SUVN-G3031): Suven Life Sciences

  • NLS-2: NLS Pharmaceutics

  • ALKS 2680: Alkermes, Inc.

  • JZP258 (XYWAV): Jazz Pharmaceuticals

  • TS-091 5mg: Taisho Pharmaceutical

  • JZP-258: Jazz Pharma

  • SUVN-G3031: Suven Life Sciences Limited

  • JNJ-17216498: Alza Corporation, DE, USA

  • Modafinil: Cephalon

  • sodium oxybate: Orphan Medical

  • THN102 300/3: Theranexus

  • Mazindol: NLS Pharmaceutics

  • AXS-12 (Reboxetine): Axsome Therapeutics, Inc

  • TAK-861: Takeda

  • PF-03654746: Pfizer

  • FT218: Avadel

  • BTD-001: Balance Therapeutics

 

Discover more about therapies set to grab major Narcolepsy market share @ Narcolepsy Treatment Market

 

Narcolepsy Market Strengths

  • Many pharmaceutical companies are continuously researching and innovating the treatment regimens for eradicating the current unmet needs in narcolepsy.

  • The increasing prevalence of narcolepsy, for instance, knee pain associated with osteoarthritis, is primarily contributed by the increase in the aging population that will likely impact the market in the near future

 

Narcolepsy Market Opportunities

  • Identify potential therapeutic targets and strategies for improving quality of life, and restore functional levels of those who suffer from Narcolepsy

  • To understand the transition from acute to narcolepsy, how peripheral and central sensitization is manifested, and how they can be assessed

 

Scope of the Narcolepsy Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Narcolepsy Companies: NLS Pharmaceutics, Alkermes, Inc., Jazz Pharmaceuticals, Taisho Pharmaceutical, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical, Theranexus, NLS Pharmaceutics, Axsome Therapeutics, Inc, Takeda, Pfizer, Avadel, Balance Therapeutics, and others

  • Key Narcolepsy Therapies: QUILIENCE (mazindol ER), Samelisant (SUVN-G3031), NLS-2, ALKS 2680, JZP258 (XYWAV), TS-091 5mg, JZP-258, SUVN-G3031, JNJ-17216498, Modafinil, sodium oxybate, THN102 300/3, Mazindol, AXS-12 (Reboxetine), TAK-861, PF-03654746, FT218, BTD-001, and others

  • Narcolepsy Therapeutic Assessment: Narcolepsy current marketed and Narcolepsy emerging therapies

  • Narcolepsy Market Dynamics: Narcolepsy market drivers and Narcolepsy market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Narcolepsy Unmet Needs, KOL’s views, Analyst’s views, Narcolepsy Market Access and Reimbursement

 

To know more about Narcolepsy companies working in the treatment market, visit @ Narcolepsy Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Narcolepsy Market Report Introduction

2. Executive Summary for Narcolepsy

3. SWOT analysis of Narcolepsy

4. Narcolepsy Patient Share (%) Overview at a Glance

5. Narcolepsy Market Overview at a Glance

6. Narcolepsy Disease Background and Overview

7. Narcolepsy Epidemiology and Patient Population

8. Country-Specific Patient Population of Narcolepsy

9. Narcolepsy Current Treatment and Medical Practices

10. Narcolepsy Unmet Needs

11. Narcolepsy Emerging Therapies

12. Narcolepsy Market Outlook

13. Country-Wise Narcolepsy Market Analysis (2020–2034)

14. Narcolepsy Market Access and Reimbursement of Therapies

15. Narcolepsy Market Drivers

16. Narcolepsy Market Barriers

17. Narcolepsy Appendix

18. Narcolepsy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/